Immunological long-term follow-up of neuroblastoma stage IV patients after anti-GD2 CH14.18 antibody treatment.

被引：0
|
作者：
Kayser, Simone
Icheva, Vanya
Stevanovic, Stefan
Siebert, Nikolai
Feucht, Judith
Lode, Holger N.
Handgretinger, Rupert
Feuchtinger, Tobias
机构：
[1] Univ Childrens Hosp, Tubingen, Germany
[2] Univ Tubingen, Dept Immunol, Inst Cell Biol, Tubingen, Germany
[3] Univ Med Greifswald, Greifswald, Germany
[4] Ernst Moritz Arndt Univ Greifswald, Univ Med Ctr, Greifswald, Germany
[5] Univ Munich, Dr von Haunersches Kinderspital, Dept Pediat Hematol Oncol, Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.3029
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3029
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Ocular symptoms in children treated with human-mouse chimeric anti-GD2 mAb ch14.18 for neuroblastoma
    Kremens, B
    Hero, B
    Esser, J
    Weinel, P
    Filger-Brillinger, J
    Fleischhack, G
    Graf, N
    Grüttner, HP
    Niemeyer, C
    Schulz, A
    Wickmann, L
    Berthold, F
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2002, 51 (02) : 107 - 110
  • [22] INTERLEUKIN-2 ADDS TOXICITY BUT NO MEASURABLE ACTIVITY IN RELAPSED/REFRACTORY NEUROBLASTOMA PATIENTS TREATED WITH LONG-TERM INFUSION OF ANTI GD2 ANTIBODY CH14.18/CHO
    Lode, H.
    Siebert, N.
    Eger, C.
    Schuster, M.
    Janzek, E.
    Loibner, H.
    PEDIATRIC BLOOD & CANCER, 2015, 62 : S224 - S224
  • [23] Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment
    Seitz, Christian Martin
    Flaadt, Tim
    Mezger, Markus
    Lang, Anne-Marie
    Michaelis, Sebastian
    Katz, Marie
    Syring, Desiree
    Joechner, Alexander
    Rabsteyn, Armin
    Siebert, Nikolai
    Troschke-Meurer, Sascha
    Zumpe, Maxi
    Lode, Holger N.
    Yang, Sile F.
    Atar, Daniel
    Mast, Anna-Sophia
    Scheuermann, Sophia
    Heubach, Florian
    Handgretinger, Rupert
    Lang, Peter
    Schlegel, Patrick
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [24] Survival of Neuroblastoma Patients Treated by Long-Term Infusion of Anti-GD2 Antibody CH14.18/CHO Correlate with Killer-Cell Ig-Like Receptor (KIR) Genotypes and Fcγ-Receptor Polymorphisms
    Lode, H.
    Troschke-Meurer, S.
    Valteau-Couanet, D.
    Garaventa, A.
    Gray, J.
    Castel, V.
    Yaniv, I.
    Siebert, N.
    Eger, C.
    Juettner, M.
    Kietz, S.
    Karoline, E.
    Janzek, E.
    Loibner, H.
    Mueller, I.
    Ladenstein, R.
    PEDIATRIC BLOOD & CANCER, 2016, 63 : S39 - S39
  • [25] Survival of neuroblastoma patients treated by long-term infusion of anti-GD2 antibody ch14.18/CHO and killer-cell Ig-like receptor (KIR) genotypes and Fcγ-receptor polymorphisms.
    Lode, Holger N.
    Loibner, Hans
    Troschke-Meurer, Sascha
    Couanet, Dominique Valteau
    Garaventa, Alberto
    Gray, Juliet
    Castel, Victoria
    Yaniv, Isaac
    Siebert, Nikolai
    Eger, Christin
    Juettner, Madlen
    Kietz, Silke
    Ehlert, Karoline
    Janzek, Evelyne
    Mueller, Ina
    Ladenstein, Ruth
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
  • [26] SURVIVAL FOLLOWING LONG-TERM INFUSION OF ANTI-GD2 ANTIBODY CH14.18/CHO IN COMBINATION WITH INTERLEUKIN-2 IN A PILOT COHORT OF HIGH-RISK NEUROBLASTOMA PATIENTS CORRELATES WITH FC-GAMMA RECEPTOR POLYMORPHISMS
    Lode, H. N.
    Jensen, C.
    Endres, S.
    Pill, L.
    Siebert, N.
    Brock, P.
    Valteau-Couanet, D.
    Loibner, H.
    Ladenstein, R.
    Mueller, I.
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S122 - S122
  • [27] Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
    Simon, Thorsten
    Hero, Barbara
    Faldum, Andreas
    Handgretinger, Rupert
    Schrappe, Martin
    Klingebiel, Thomas
    Berthold, Frank
    BMC CANCER, 2011, 11
  • [28] Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
    Thorsten Simon
    Barbara Hero
    Andreas Faldum
    Rupert Handgretinger
    Martin Schrappe
    Thomas Klingebiel
    Frank Berthold
    BMC Cancer, 11
  • [29] Effect of PD1/PD-L1 checkpoint blockade on efficacy of anti-GD2 antibody ch14.18/CHO in neuroblastoma.
    Lode, Holger N.
    Zumpe, Maxi
    Juettner, Madlen
    Troschke-Meurer, Sascha
    Loibner, Hans
    Siebert, Nikolai
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] ANTI-GD2-ANTIBODY CH14.18 OR RETINOIC ACID AS CONSOLIDATION THERAPY IN HIGH-RISK NEUROBLASTOMA
    Simon, Thorsten
    Hero, Barbara
    Handgretinger, Rupert
    Schrappe, Martin
    Klingebiel, Thomas
    Fruehwald, Michael
    Frank, Berthold
    PEDIATRIC BLOOD & CANCER, 2011, 57 (05) : 789 - 789
12345